Journal
MULTIPLE SCLEROSIS
Volume 6, Issue 6, Pages 373-377Publisher
NATURE PUBLISHING GROUP
DOI: 10.1191/135245800701566331
Keywords
multiple sclerosis; magnetic resonance imaging; brain atrophy
Categories
Funding
- NINDS NIH HHS [P01 NS38667] Funding Source: Medline
- PHS HHS [R01-26321] Funding Source: Medline
Ask authors/readers for more resources
Brain atrophy measurement con Provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability A follow-up study was Performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFN beta -1a (Avonex) in relapsing-remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal faction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time Points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-vp exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease Progression in relapsing-remitting MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available